XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.21.2

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Segment Reporting [Abstract] |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] | A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
MedSurg | $ | 917 |  |  | $ | 825 |  | $ | 2,725 |  |  | $ | 2,175
Rhythm and Neuro | 819 |  |  | 757 |  | 2,436 |  |  | 1,985
Cardiovascular | 1,196 |  |  | 1,002 |  | 3,588 |  |  | 2,862
Total net sales of reportable segments | 2,932 |  |  | 2,584 |  | 8,748 |  |  | 7,021
All other (Specialty Pharmaceuticals)(1) | — |  |  | 74 |  | 13 |  |  | 183
Net sales | $ | 2,932 |  |  | $ | 2,659 |  | $ | 8,761 |  |  | $ | 7,204
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
MedSurg | $ | 338 |  |  | $ | 307 |  | $ | 1,033 |  |  | $ | 738
Rhythm and Neuro | 160 |  |  | 165 |  | 476 |  |  | 296
Cardiovascular | 361 |  |  | 208 |  | 1,117 |  |  | 593
Total operating income of reportable segments | 859 |  |  | 680 |  | 2,626 |  |  | 1,628
All other (Specialty Pharmaceuticals)(1) | — |  |  | 49 |  | 4 |  |  | 124
Unallocated amounts: |  |  |  |  |  |  |
Corporate expenses, including hedging activities | (109) |  |  | (108) |  | (438) |  |  | (330)
Intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), and certain litigation-related net charges (credits) and EU MDR implementation costs | (178) |  |  | (629) |  | (624) |  |  | (957)
Amortization expense | (184) |  |  | (197) |  | (549) |  |  | (595)
Operating income (loss) | 387 |  |  | (205) |  | 1,019 |  |  | (130)
Other expense, net | 95 |  |  | (22) |  | (62) |  |  | (256)
Income (loss) before income taxes | $ | 483 |  |  | $ | (227) |  | $ | 957 |  |  | $ | (386)
(1) On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes for the first nine months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.
Operating income margin of reportable segments | Three Months Ended September 30, |  | Nine Months Ended September 30,
2021 |  | 2020 |  | 2021 |  | 2020
MedSurg | 36.8 | % |  | 37.2 | % |  | 37.9 | % |  | 33.9 | %
Rhythm and Neuro | 19.5 | % |  | 21.9 | % |  | 19.5 | % |  | 14.9 | %
Cardiovascular | 30.2 | % |  | 20.8 | % |  | 31.1 | % |  | 20.7 | %

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration